ALGS
Aligos TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
ALGS vs peer average
48/100
ALGS vs. peer average (D vs. D)
Grade spread
B 2 · C 1 · D 3 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
ABUS is the first available peer comparator.
Contextual HBV-focused antiviral operating peer with a different modality; useful for competitive and clinical context, not as a standalone valuation anchor.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ALGS
Aligos Therapeutics
ABUS
Arbutus Biopharma
Grade
D
B
Momentum
65
25
Value
41
55
Sentiment
54
69
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs ABUS
ALGS / ABUS
Grade Position
In line
ALGS vs. peer average (D vs. D)
48/100
Momentum
65
ALGSValue
41
ABUSSentiment
54
ABUSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ALGS
ABUS is the first peer returned for this comparison set.